Family health risk ads prompt changes

Share this article:
Drug ads emphasizing familial health risks prompt at-risk patients to adjust their lifestyles, not just pop a pill, a study found.

Researchers from the University of Georgia's Department of Speech Communication and the University of Pennsylvania's Annenberg School for Communication observed the responses of 400 adults to drug ads for clues as to how ads with hereditary risk cues affect patient outlooks on health and what actions they prompted.

They wanted to know if ads citing hereditary risk make patients fatalistic or not, and whether they prompt changes in diet and exercise or just medication.

Study participants were shown modified ads for Merck's Vytorin, for high cholesterol, Warner Chilcott's Actonel, for osteoporosis, and Bayer aspirin, for heart attacks. Copy was modified for participants in the control segment—the “two sources” of high cholesterol cited in the Vytorin ad's tagline, for example, were changed from “food and family” to “food and inactivity.”

The upshot? Rather than feeling fatalistic about their chances of developing a disease, participants viewing the unaltered ads were more likely to say that they planned to eat healthier and exercise more.

“In a way, we do not believe we are like our parents in that the respondents felt they can overcome family risks to health issues by both pursuing a healthy lifestyle and investigating the use of advertised medications,” said Dr. Minsun Shim of the University of Georgia.

She said that citing “genetic” factors rather than “family” risks is a better bet for promoting drugs, but that familial language cues lifestyle adjustments.

More research is needed into the correlation between willingness to change lifestyle and willingness to seek medical assistance, said Dr. Shim.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...